The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Managing attention deficit hyperactivity disorder in adults using illicit psychostimulants: A systematic review
Open accessAbstract
Context: Attention deficit hyperactivity disorder and stimulant use disorder commonly co-exist, and appropriate treatments have not been well established. Objective: To provide guidance for treatment of co-existing attention deficit hyperactivity disorder and stimulant use disorder. Data sources: A systematic review of published English articles using MEDLINE, EMBASE, CINAHL, PsycINFO and Cochrane, utilising consistent search terms. Study selection: Randomised controlled trials, comparing any treatment arm with a control group, for participants meeting Diagnostic and Statistical Manual of Mental Disorders or equivalent criteria for both attention deficit hyperactivity disorder and stimulant use disorder. Results: Eight trials were identified for inclusion in this review. Four of eight studies showed improvement in attention deficit hyperactivity disorder outcome measures compared with placebo. Two of six studies that reported substance use outcomes showed improvement in treatment arms compared with placebo. Studies to show effect tended to be those with the highest treatment dosage. Conclusion: Evidence for the efficacy of treatment of patients with comorbid stimulant use disorder and attention deficit hyperactivity disorder is limited. Promising outcomes need replication in further studies utilising higher treatment dosage.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the open label trial, naltrexone was administered every four weeks, whereas in the RCT it was administered every three weeks to reduce potential blood level fluctuations.120,121”
From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [121]
In the citing paper
“The available research used relatively high doses of bupropion (ie, 450 mg of an extended-release formulation).”
From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [121]
In the citing paper
“While bupropion and naltrexone are generally well tolerated, both studies reported a moderate number of adverse events.”
From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [121]
In the citing paper
“Both studies-one open label and one RCT-included patients with moderate to severe methamphetamine use disorder.”
From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [121]
In the citing paper
“While the evidence for bupropion alone is somewhat weak in patients with ATS use disorder, two recent studies using combination bupropion and naltrexone have shown more promise in terms of stimulant use outcomes.120,121”
From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [121]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Journal of Clinical Psychiatry
(2018) · Journal of Clinical Psychiatry · doi:10.5505/kpd · Cited by 13,651
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00136 · Cited by 10,349
Mechanisms of neurotransmitter release by amphetamines: A review
Sulzer, D., Sonders, M. S., Poulsen, N. W., & Galli, A. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.04.003 · Cited by 1,209
Wilens, T. E., Faraone, S. V., Biederman, J., & Gunawardene, S. (2003) · Pediatrics · doi:10.1542/peds.111.1.179 · Cited by 872
Psychology Research and Behavior Management
(2020) · Psychology Research and Behavior Management · doi:10.2147/prbm · Cited by 701
Volkow, N. D. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950180042006 · Cited by 575 · cited 2×
“Methylphenidate has an action similar to cocaine, with comparable affinity to the dopamine transporter, rate of brain uptake and levels of synaptic dopamine, but differing markedly in their rate of clearance, half-life and mechanism of effect on the dopamine transporter (Calipari et al., 2014; Kollins et al., 2001; Vo…”
Backgroundvan Emmerik-van Oortmerssen, K., van de Glind, G., van den Brink, W., Smit, F., Crunelle, C. L., Swets, M., & Schoevers, R. A. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.12.007 · Cited by 535 · cited 3×
“The combination of ADHD and substance use disorders results in high risk of severe emotional and interpersonal problems (Van Emmerik-van Oortmerssen et al., 2014).”
BackgroundInfluentialMortality, ADHD, and Psychosocial Adversity in Adults With Childhood ADHD: A Prospective Study
Barbaresi, W. J., Colligan, R. C., Weaver, A. L., Voigt, R. G., Killian, J. M., & Katusic, S. K. (2013) · Pediatrics · doi:10.1542/peds.2012-2354 · Cited by 401
Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review
Kollins, S. H., MacDonald, E. K., & Rush, C. R. (2001) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(01)00464-6 · Cited by 365
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Storebø, O. J., Ramstad, E., Krogh, H. B., Nilausen, T. D., Skoog, M., Holmskov, M., Rosendal, S., Groth, C., Magnusson, F. L., Moreira-Maia, C. R., et al. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009885.pub2 · Cited by 347
Research works printed but not linked: 1
- Punja S, Shamseer L, Hartling L, et al. (2016) Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database of Systematic Reviews. Epub ahead of print 4 February 2016. DOI: 009910.001002/14651858. · doi:10.001002/14651858
Cited by
The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder
(2024) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001299 · Cited by 78
Walker, S., Lancaster, K., Stoove, M. A., Higgs, P., & Wilson, M. (2018) · Contemporary Drug Problems · doi:10.1177/0091450918777280 · Cited by 28
van der Burg, D., Crunelle, C. L., Matthys, F., & van den Brink, W. (2019) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000513 · Cited by 25
The Use of Lisdexamfetamine to Treat ADHD in a Patient with Stimulant (Methamphetamine) Use Disorder
Levine, J., & Swanson, H. (2023) · Case Reports in Psychiatry · doi:10.1155/2023/5574677 · Cited by 8
Więckiewicz, G., Stokłosa, I., Stokłosa, M., Więckiewicz, W., Gorczyca, P. W., & Gondek, T. M. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1184023 · Cited by 7
Metadata
- Authors
- Cook, J., Lloyd-Jones, M., Arunogiri, S., Ogden, E., & Bonomo, Y.
- Affiliations
- Western Health (AU)
- Department of Addiction Medicine, St Vincent’s Hospital Melbourne, Fitzroy, VIC, Australia
- Eastern Health (AU)
- St Vincent's Hospital Melbourne (AU)
- The University of Melbourne (AU)
- Corresponding author
- Cook, Jon
- Venue
- Australian & New Zealand Journal of Psychiatry
- Publisher
- SAGE Publications
- Published
- 2017-06-22
- Volume
- 51
- Issue
- 9
- Pages
- 876-885
- ISSN
- 0004-8674 (ISSN-L)
- 1440-1614
- OpenAlex
- W2661909017
- Cited by
- 13
- References
- 48
- Citations by year
- 2025: 1 · 2024: 3 · 2023: 3 · 2021: 2 · 2020: 2 · 2019: 1 · 2018: 1
- FWCI
- 0.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Australian & New Zealand Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Swinburne figshare (Swinburne University of Technology) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- attention deficit hyperactivity disorder, stimulant use disorder, comorbidities, treatment efficacy, substance use outcomes, ADHD treatment
- MeSH terms
- Adult, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Humans, Illicit Drugs, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Managing attention deficit hyperactivity disorder in adults using illicit psychostimulants: A systematic review. https://app.cochat.ai/papers/10.1177/0004867417714878
- The paper
- Cook, J., Lloyd-Jones, M., Arunogiri, S., Ogden, E., & Bonomo, Y. (2017). Managing attention deficit hyperactivity disorder in adults using illicit psychostimulants: A systematic review. Australian & New Zealand Journal of Psychiatry. https://doi.org/10.1177/0004867417714878
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.